The Gut Microbial Metabolite Trimethylamine N-Oxide is Linked to Specific Complications of Systemic Sclerosis
Albert Stec,Magdalena Maciejewska,Karolina Paralusz-Stec,Milena Michalska,Joanna Giebułtowicz,Lidia Rudnicka,Mariusz Sikora
DOI: https://doi.org/10.2147/JIR.S409489
IF: 4.5
2023-05-02
Journal of Inflammation Research
Abstract:Albert Stec, 1 Magdalena Maciejewska, 1 Karolina Paralusz-Stec, 1 Milena Michalska, 2 Joanna Giebu&lstroktowicz, 3 Lidia Rudnicka, 1 Mariusz Sikora 4 1 Department of Dermatology, Medical University of Warsaw, Warsaw, Poland; 2 Department of General, Vascular and Transplant Surgery, Medical University of Warsaw, Warsaw, Poland; 3 Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland; 4 National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland Correspondence: Mariusz Sikora, National Institute of Geriatrics, Rheumatology and Rehabilitation, Sparta&nacuteska 1, Warsaw, 02-637, Poland, Tel +48 22 670 91 00, Fax +48 22 844 77 97, Email Background: Systemic sclerosis (SSc) is a rare immune-mediated connective tissue disease characterized by fibrosis of the skin and internal organs, whose pathogenesis is not fully understood. Recent studies have revealed dysbiosis in patients with systemic sclerosis and have indicated the possible role of the microbiota and its metabolites in the pathogenesis of the disease. Trimethylamine N-oxide (TMAO) is a compound produced by dysbiotic microbiota observed at higher concentrations in several autoimmune diseases. Objective: To determine concentrations of the bacteria-derived metabolite TMAO in patients with systemic sclerosis and to assess possible correlation between TMAO and a specific manifestation of the disease. Patients and Methods: The study included 63 patients with SSc and 47 matched control subjects. The concentration of TMAO was measured with high-performance liquid chromatography. Results: Plasma TMAO level was significantly increased in patients with SSc (283.0 [188.5– 367.5] ng/mL versus 205.5 [101.0– 318.0] ng/mL; p < 0.01). An increased concentration of TMAO was observed in patients with concomitant interstitial lung disease (ILD) (302.0 ng/mL [212.0– 385.5] ng/mL versus 204.0 [135.5– 292.0] ng/mL; p < 0.01) and esophageal dysmotility (289.75 [213.75– 387.5] ng/mL versus 209.5 ng/mL [141.5– 315.0] ng/mL; p < 0.05) compared to patients without these complications. Furthermore, TMAO concentration exhibited significant correlation with markers of heart involvement (left ventricle ejection fraction, NT-proBNP), marker of ILD severity and Scleroderma Clinical Trials Consortium Damage Index. Conclusion: The concentration of TMAO, gut microbiota-associated metabolite, is increased in systemic sclerosis, particularly in patients with advanced organ involvement. This is the first study evaluating plasma TMAO in systemic sclerosis. Bacterial metabolites may be a link between dysbiosis and organ involvement in the course of the disease. Modulation of gut bacterial-derived metabolites may represent a new therapeutic approach in the management of systemic sclerosis. Keywords: gut microbiota, systemic sclerosis, trimethylamine N-oxide, bacterial metabolites, dysbiosis, damage index Systemic sclerosis (SSc) is an immune-mediated connective tissue disease. It is characterized by fibrosis of the skin, internal organs (eg, lungs, gastrointestinal tract) and vascular abnormalities. Based on the extent of skin involvement, SSc is commonly classified into two main subsets: diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc). 1–3 To date, the pathology of systemic sclerosis remains not fully elucidated and there is a lack of established biomarkers of SSc severity and organ involvement. 4,5 Early intervention with immunomodulators in patients with SSc may lead to better outcome. 6,7 Recently, there has been a growing number of studies presenting alteration in intestinal microbiota (dysbiosis) in patients with systemic sclerosis and its impact on the disease. Gut microbiota profiling in systemic sclerosis revealed significant changes in its biodiversity and composition compared to healthy controls. Patients with SSc are characterized by an increased abundance of Fusobacterium, Desulfovibrio, Ruminococcus , and Lactobacillus , and a decreased abundance of Faecalibacterium . 8–10 Furthermore, some of the SSc complications, such as interstitial lung disease (ILD) and esophageal dysmotility, are associated with more pronounced dysbiosis. 11,12 Currently, research on modifying microbiota in SSc is emerging. Some studies have shown that probiotics or fecal microbiota transplantation may improve SSc, particularly gastrointestinal symptoms of the disease. 13–16 In systemic sclerosis, metabolic proficiencies of gut microbiota also differ from the control group; 9 thus, it is high -Abstract Truncated-
immunology